200 related articles for article (PubMed ID: 18840427)
1. Pharmacological modulation of leukotriene D(4) attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Singh I; Singh N; Bansal N; Bansal S; Kumar M
Eur J Pharmacol; 2008 Nov; 598(1-3):51-6. PubMed ID: 18840427
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
3. Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.
Rehni AK; Singh N; Rachamalla M; Tikoo K
Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):605-19. PubMed ID: 22362134
[TBL] [Abstract][Full Text] [Related]
4. Modulation of src-kinase attenuates naloxone-precipitated opioid withdrawal syndrome in mice.
Rehni AK; Singh N
Behav Pharmacol; 2011 Apr; 22(2):182-90. PubMed ID: 21285874
[TBL] [Abstract][Full Text] [Related]
5. Modulation of leukotriene D4 attenuates the development of seizures in mice.
Rehni AK; Singh TG
Prostaglandins Leukot Essent Fatty Acids; 2011 Aug; 85(2):97-106. PubMed ID: 21641195
[TBL] [Abstract][Full Text] [Related]
6. Yiguanjian cataplasm attenuates opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Gao S; Gao H; Fan Y; Zhang G; Sun F; Zhao J; Li F; Yang Y; Wang K
J Tradit Chin Med; 2016 Aug; 36(4):464-70. PubMed ID: 28459510
[TBL] [Abstract][Full Text] [Related]
7. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence.
Liu J; Schulteis G
Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289
[TBL] [Abstract][Full Text] [Related]
8. Potential involvement of tyrosine phosphatase and calpain-related pathways in opioid withdrawal syndrome in mice.
Rehni AK; Singh N
Behav Pharmacol; 2012 Jun; 23(3):302-9. PubMed ID: 22495184
[TBL] [Abstract][Full Text] [Related]
9. Effects of opioid agonist and antagonist in dams exposed to morphine during the perinatal period.
Sobor M; Timár J; Riba P; Friedmann T; Király KP; Gyarmati S; Al-Khrasani M; Fürst S
Brain Res Bull; 2011 Jan; 84(1):53-60. PubMed ID: 20934489
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.
Singh P; Sharma B; Gupta S; Sharma BM
Psychopharmacology (Berl); 2015 Jan; 232(2):465-75. PubMed ID: 25059539
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological modulation of geranylgeranyltransferase and farnesyltransferase attenuates opioid withdrawal in vivo and in vitro.
Rehni AK; Singh TG
Neuropharmacology; 2013 Aug; 71():19-26. PubMed ID: 23415632
[TBL] [Abstract][Full Text] [Related]
12. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice.
Haghparast A; Khani A; Naderi N; Alizadeh AM; Motamedi F
Pharmacol Biochem Behav; 2008 Feb; 88(4):385-92. PubMed ID: 17915302
[TBL] [Abstract][Full Text] [Related]
14. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.
Bhalla S; Pais G; Tapia M; Gulati A
Can J Physiol Pharmacol; 2015 Nov; 93(11):935-44. PubMed ID: 26440527
[TBL] [Abstract][Full Text] [Related]
15. Phenylmethanesulfonyl fluoride, a serine protease inhibitor, suppresses naloxone-precipitated withdrawal jumping in morphine-dependent mice.
Nemoto W; Sato T; Nakagawasai O; Yaoita F; Silberring J; Tadano T; Tan-No K
Neuropeptides; 2013 Jun; 47(3):187-91. PubMed ID: 23290539
[TBL] [Abstract][Full Text] [Related]
16. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
18. Naloxone-precipitated withdrawal enhances ERK phosphorylation in prefrontal association cortex and accumbens nucleus of morphine-dependent mice.
Li T; Hou Y; Cao W; Yan CX; Chen T; Li SB
Neurosci Lett; 2010 Jan; 468(3):348-52. PubMed ID: 19922770
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
[TBL] [Abstract][Full Text] [Related]
20. Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice.
Bilbao A; Cippitelli A; Martín AB; Granado N; Ortiz O; Bezard E; Chen JF; Navarro M; Rodríguez de Fonseca F; Moratalla R
Psychopharmacology (Berl); 2006 Apr; 185(2):160-8. PubMed ID: 16470403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]